Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

Boehringer Ingelheim GmbH is open to more dealmaking to build its obesity portfolio even as it stays “laser-focused” on ...

Achieving weight loss within a year of initiating orlistat can reduce the risk for both incident gout and recurrent gout ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...